Fig. 2: In MGUS patients (n = 99), the first sBCMA sample collected was used to stratify patients into two groups, those with sBCMA below versus equal to or above the median sBCMA at first sample collection.
From: Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
The A PFS, and B OS are shown, stratified by the median sBCMA values at first collection.
